What was it originally approved for?

It was FDA-approved in 2001 to improve dyspnea in patients with acute decompensated heart failure, based mainly on short-term hemodynamic and symptom data.

What is the main safety concern?

Hypotension (low blood pressure) is the most consistent risk, and analyses raised concerns about worsening kidney function. Later trials showed no survival benefit.

Is it a supplement or something people can buy?

No. It is a recombinant peptide given intravenously in a hospital under monitoring, not an over-the-counter or research-peptide product.

Why is it discussed if it doesn't work well?

It is an instructive example of a biologically plausible natriuretic peptide that improved short-term numbers but failed to improve patient outcomes in a large trial, showing why hard-outcome evidence matters.

FDA-approved medicineaka Natrecor, recombinant human BNP

Nesiritide — Complete Research Guide (2026)

Last updated 2026-07-31

TL;DR

Recombinant human B-type natriuretic peptide, FDA-approved (2001) for acute decompensated heart failure but largely abandoned after neutral outcome trials.

What is Nesiritide?

Nesiritide (brand name Natrecor) is a recombinant form of human B-type natriuretic peptide (BNP) given by intravenous infusion.

It was FDA-approved in 2001 for acute decompensated heart failure to reduce dyspnea, but subsequent large trials showed no benefit on mortality or rehospitalization and a risk of hypotension.

It is now largely abandoned in clinical practice and its evidence base is considered negative for hard outcomes.

How does Nesiritide work?

Nesiritide binds natriuretic peptide receptors and raises intracellular cyclic GMP, producing arterial and venous vasodilation that lowers pulmonary capillary wedge pressure and systemic vascular resistance.

It also has natriuretic and diuretic effects, but these did not translate into improved clinical outcomes.

What does the research say about Nesiritide?

In the VMAC trial, nesiritide reduced pulmonary capillary wedge pressure and modestly improved dyspnea versus placebo over the first hours of treatment. ^[1]
Early controlled studies showed favorable short-term hemodynamic effects (reduced filling pressures) in decompensated heart failure. ^[3]
The large ASCEND-HF trial found nesiritide produced only a small, non-significant effect on dyspnea and NO reduction in death or heart-failure rehospitalization. ^[2]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

[1] Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial — Publication Committee for the VMAC Investigators, JAMA 2002. (Randomized controlled trial (VMAC))
[2] Effect of nesiritide in patients with acute decompensated heart failure — O'Connor CM et al., New England Journal of Medicine 2011. (Large randomized controlled trial (ASCEND-HF))
[3] Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure — Colucci WS et al., New England Journal of Medicine 2000. (Randomized controlled trial)
[4] Nesiritide for the treatment of decompensated heart failure — Colucci WS et al., Journal of Cardiac Failure 2001. (Clinical review/analysis)
[5] Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure — Sackner-Bernstein JD et al., Circulation 2005. (Pooled meta-analysis of randomized trials)
[6] The dose-dependent effect of nesiritide on renal function in patients with acute decompensated heart failure: a systematic review and meta-analysis of randomized controlled trials — Xiong B et al., PLOS ONE 2015. (Systematic review and meta-analysis)

Dosing context

This is not medical advice or a usage recommendation. Dosing figures are reported research context only, cited from the published literature.

This is context only and not medical advice: in trials nesiritide was given intravenously, sometimes with an initial bolus followed by a continuous infusion, strictly in a monitored hospital setting because of the blood-pressure-lowering effect.

It has no role as a self-administered or outpatient agent.

Side effects & safety profile

The main acute safety concern is hypotension, which was more frequent with nesiritide than with comparators and could be prolonged.

Pooled and observational analyses also raised concerns about worsening renal function and possible harm, and the definitive ASCEND-HF trial showed no mortality benefit.

These findings, taken together, led to its effective abandonment in routine heart-failure care.

Stacking & combinations

Nesiritide is an intravenous hospital drug that fell out of use after negative outcome trials, and it is not something to combine with other agents outside of supervised inpatient care.

Finding Nesiritide vendors

This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.

Choose your country

We never list placeholder vendors. Pick your country to see neutral regulatory context.

Browse the directory

User reviews

No reviews yet

Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.

Frequently asked questions

Rarely. After the ASCEND-HF trial showed no benefit on death or rehospitalization and confirmed a hypotension risk, nesiritide was largely abandoned in routine heart-failure treatment.

References

[1] Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial — Publication Committee for the VMAC Investigators, JAMA 2002. PMID: 11911755. View sourceStudy: Randomized controlled trial (VMAC)Nesiritide lowered pulmonary capillary wedge pressure and modestly improved dyspnea versus placebo early after infusion.
[2] Effect of nesiritide in patients with acute decompensated heart failure — O'Connor CM et al., New England Journal of Medicine 2011. PMID: 21732835. View sourceStudy: Large randomized controlled trial (ASCEND-HF)Nesiritide did not reduce death or rehospitalization, had only a marginal dyspnea effect, and increased hypotension.
[3] Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure — Colucci WS et al., New England Journal of Medicine 2000. PMID: 10911006. View sourceStudy: Randomized controlled trialNesiritide improved short-term hemodynamics and symptoms in decompensated heart failure.
[4] Nesiritide for the treatment of decompensated heart failure — Colucci WS et al., Journal of Cardiac Failure 2001. PMID: 11264555. View sourceStudy: Clinical review/analysisReviews the hemodynamic and symptomatic effects supporting nesiritide's original approval.
[5] Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure — Sackner-Bernstein JD et al., Circulation 2005. PMID: 15781736. View sourceStudy: Pooled meta-analysis of randomized trialsNesiritide was associated with an increased risk of worsening renal function.
[6] The dose-dependent effect of nesiritide on renal function in patients with acute decompensated heart failure: a systematic review and meta-analysis of randomized controlled trials — Xiong B et al., PLOS ONE 2015. PMID: 26107522. View sourceStudy: Systematic review and meta-analysisHigher nesiritide doses were associated with adverse effects on renal function.

This article is for educational and research purposes only. Peptides discussed here are not approved for human consumption by the FDA, EMA, or equivalent regulators outside of specific clinical contexts. Always consult a licensed medical professional before any therapeutic use.